Tazverik Approved for Epithelioid Sarcoma.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 2, p. 34
- Publication type:
- Article
Works matching IS 21644403 AND DT 2020 AND VI 10 AND IP 2
Results: 19
1
2
FDA Approves Ayvakit for Gastrointestinal Stromal Tumor with a Rare Mutation.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 2, p. 33
- Publication type:
- Article
3
Keytruda Now Indicated for the Treatment of BCG-Unresponsive, High-Risk, Non-Muscle-Invasive Bladder Cancer.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 2, p. 33
- Publication type:
- Article
4
Greater Social Support May Help Alleviate Pain in Patients with Cancer.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 2, p. 31
- By:
- Publication type:
- Article
5
Palliative Care Improves Pain Control with Less Opioids in Advanced Cancer.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 2, p. 30
- By:
- Publication type:
- Article
6
Five-Year Survival Rates with BRAF-MEK Inhibitors in Metastatic Melanoma with BRAF Mutation.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 2, p. 28
- Publication type:
- Article
7
Selinexor-Dexamethasone Combination Improves Outcomes in Patients with Multiple Myeloma Refractory to 3 Drug Classes.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 2, p. 28
- Publication type:
- Article
8
Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 2, p. 25
- By:
- Publication type:
- Article
9
Dual-Targeted CAR T-Cell Therapy Leads to Very High Response Rates in Relapsed or Refractory Multiple Myeloma.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 2, p. 24
- By:
- Publication type:
- Article
10
Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy Prevents Cytokine Release Syndrome.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 2, p. 22
- By:
- Publication type:
- Article
11
Mosunetuzumab, a Dual-Targeted Antibody, Shows Complete Remissions in Relapsed/Refractory NHL After CAR T-Cell Therapy.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 2, p. 21
- By:
- Publication type:
- Article
12
Best Practices for Integrating Biosimilars into Your Oncology Practice.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 2, p. 19
- By:
- Publication type:
- Article
13
Payers' Perspectives on Value in Cancer Care.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 2, p. 18
- Publication type:
- Article
14
Barriers to Value-Based Contracting in Oncology.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 2, p. 17
- Publication type:
- Article
15
First National Study: Geographic Socioeconomic Disparities Mirror Substantial Gaps in Survival in Children with AML.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 2, p. 14
- By:
- Publication type:
- Article
16
Nivolumab Bridges Patients with Relapsed/Refractory Hodgkin Lymphoma to AHCT.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 2, p. 12
- By:
- Publication type:
- Article
17
Real-World Healthcare Utilization and Costs Support Broader Use of CAR T-Cell Therapy.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 2, p. 1
- By:
- Publication type:
- Article
18
Tazemetostat Demonstrates Antitumor Activity in Relapsed/Refractory Follicular Lymphoma.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 2, p. 1
- By:
- Publication type:
- Article
19
Stepping into the Unknown.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 2, p. 1
- By:
- Publication type:
- Article